卵巢癌组织中LncRNA UCA1的表达及意义

Expression of LncRNA UCA1 in ovarian cancer and its clinicopathological significance

目的探讨长链非编码RNA(long non-coding RNAs,LncRNA)尿路上皮癌胚抗原1(urothelial carcinoma associated gene 1,UCA1)在卵巢癌组织中的表达及临床病理意义。方法回顾性分析皖南医学院第一附属医院/弋矶山医院2015年1月~2018年3月收治的48例卵巢癌患者的临床病理资料,同时与15例卵巢交界性肿瘤组织、20例卵巢良性肿瘤组织、20例正常卵巢组织进行比较分析。采用qRT-PCR检测卵巢癌组织、卵巢交界性肿瘤组织、卵巢良性肿瘤组织、正常卵巢组织中UCA1的表达量,并分析UCA1表达与卵巢癌临床病理特征的关系。结果48例卵巢癌组织中UCA1的平均表达量(12.90±2.60)均明显高于卵巢交界性肿瘤组织(4.73±1.10)、卵巢良性肿瘤(2.85±0.99)、卵巢正常组织(2.30±1.13)(P<0.05);UCA1在卵巢交界性肿瘤组织中的表达高于卵巢良性肿瘤、正常卵巢组织(P<0.05);卵巢良性肿瘤与正常卵巢组织中UCA1的表达差异无统计学意义(P>0.05)。结论LncRNA UCA1在卵巢癌组织中高表达,可能促进卵巢癌细胞的侵袭及转移,可作为卵巢癌临床治疗的潜在靶向和预后不良的分子标志物。

Purpose To investigate the expression and clinicopathological significance of LncRNA UCA1 in ovarian cancer.Methods The clinical and pathological data of 48 patients with ovarian cancer admitted to the First Affiliated Hospital/Yijishan Hospital of Wannan Medical College from January 2015 to March 2018 were retrospectively analyzed,and 15 cases of ovarian borderline tumor,20 cases of benign ovarian tumor and 20 cases of normal ovarian tissue were compared and analyzed.The expression levels of UCA1 in ovarian tissues,ovarian borderline tumor tissues,benign tumor tissues and normal ovarian tissues were detected by qRT-PCR,and the relationship between UCA1 expression and the clinicopathological characteristics of ovarian cancer was analyzed.Results The average expression of UCA1 in 48 ovarian cancer tissues(12.90±2.60)was significantly higher than that in ovarian borderline tumor tissues(4.73±1.10),benign ovarian tumor tissues(2.85±0.99)and normal ovarian tissues(2.30±1.13)(P<0.05).UCA1 expression in ovarian borderline tumor tissues was higher than that in benign ovarian tumor and normal ovarian tissues(P<0.05).There was no significant difference in UCA1 expression between benign ovarian tumor and normal ovarian tissue(P>0.05).Conclusion LncRNA UCA1 is highly expressed in ovarian cancer tissues,which may promote the invasion and metastasis of ovarian cancer cells,and may be a potential target for clinical treatment of ovarian cancer and a molecular marker of poor prognosis.